Across TCGA pan-cancer cohorts, COL6A6 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated COL6A6 data layer compared with 21 for mass-spec protein and 12 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher COL6A6 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated COL6A6 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

LUAD, PDAC, and HNSC are the cancer types where COL6A6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	II,III,IV	0.808	1.000	.014	20	view →
PDAC	DFS	Quartile	III,IV	1.000	0.432	.004	12	view →
HNSC	DFS	Median	All	1.000	0.393	.018	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: COL6A6 tumor-vs-normal RNA expression · all COL6A6 data types